Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLC7A5 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical
01
Overview
SLC7A5 siRNA is a small interfering RNA (siRNA) designed to target and knock down the expression of solute carrier family 7 member 5 (SLC7A5, also known as L-type amino acid transporter 1 or LAT1). SLC7A5 is a sodium-independent transporter that forms a heterodimeric complex with SLC3A2 (CD98) to mediate the cellular uptake of large neutral amino acids, such as leucine, phenylalanine, and tyrosine. Upregulation of SLC7A5 is observed in various malignancies, including endocrine therapy-resistant breast cancer, where it supports metabolic reprogramming, cell proliferation, and survival. SLC7A5 siRNA is widely utilized as a research-use-only laboratory tool to investigate the functional role of SLC7A5 in cancer cell growth, drug resistance, and metabolic pathways.
- Other names
- LAT1 siRNALAT-1 siRNALAT 1 siRNASLC7A5 small interfering RNASLC-7A5 small interfering RNASLC 7A5 small interfering RNAsolute carrier family 7 member 5 siRNA
02
Targets
SLC7A5 (Large neutral amino acid transporter small subunit 1)SLC3A2 (Solute carrier family 3 member 2)
Beyond the preview
Go deeper on SLC7A5 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC7A5 siRNA.